Ionic Liquid-Amphotericin B Composite for Resistant Fungal Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antifungal drugs, particularly Amphotericin B, face challenges with toxicity, bioavailability issues, and increasing resistance from fungal pathogens like Candida auris, especially in immunocompromised patients, necessitating the development of more effective and less toxic antifungal agents.
Innovation Solution
The use of ionic liquids, specifically imidazo[1,2-a]pyridinium bromides with varying alkyl chain lengths, in combination with Amphotericin B, to enhance antifungal activity and overcome resistance, forming a pharmaceutical composition that inhibits fungal growth and treats infections effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Amphotericin B is used to treat invasive fungal infections, then antifungal efficacy is improved, but nephrotoxicity and severe side effects worsen
Solution Approach 1:
The patent combines Amphotericin B with ionic liquids to create a composite antifungal formulation. The ionic liquid component (containing imidazolium or pyridinium cations with specific alkyl chains) works synergistically with Amphotericin B to enhance antifungal activity while reducing the required dose of Amphotericin B, thereby minimizing nephrotoxicity. This composite approach allows the formulation to achieve better therapeutic outcomes with lower toxicity profiles.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the antifungal formulation by introducing ionic liquids with varying alkyl chain lengths (C4-C12). These parameter changes in the formulation composition enable improved solubility and membrane permeability while maintaining or enhancing antifungal efficacy at reduced Amphotericin B concentrations, thus reducing nephrotoxicity.
2Reliability
If Amphotericin B is used to treat fungal infections, then antifungal activity is improved, but water solubility and membrane permeability worsen
Solution Approach 1:
The formulation creates a composite system where ionic liquids serve as solubilizing agents. The amphiphilic nature of ionic liquids (with hydrophobic alkyl chains and hydrophilic ionic heads) enables them to enhance the water solubility of Amphotericin B while maintaining its membrane-permeating antifungal activity. This composite formulation resolves the solubility-permeability paradox.
Solution Approach 2:
Ionic liquids act as intermediary substances that facilitate the interaction between Amphotericin B and the aqueous environment. They mediate the solubility issue by forming micellar or supramolecular structures that solubilize Amphotericin B while preserving its ability to interact with fungal cell membranes, thus improving both solubility and maintaining permeability.
3Reliability
If Amphotericin B is used at high doses to overcome drug resistance, then antifungal efficacy is improved, but toxicity worsens
Solution Approach 1:
The synergistic composite formulation of Amphotericin B and ionic liquids enables the treatment of drug-resistant fungal infections at lower Amphotericin B doses. The ionic liquid component enhances the overall antifungal activity through multiple mechanisms including membrane disruption and synergistic interaction with Amphotericin B, allowing dose reduction and thereby reducing toxicity while maintaining efficacy against resistant strains.
Solution Approach 2:
The ionic liquid component provides alternative antifungal mechanisms that complement Amphotericin B's mode of action. Rather than relying solely on high doses of Amphotericin B, the formulation uses the ionic liquid's ability to disrupt fungal cell membranes and interfere with cellular processes, creating a multi-target approach that overcomes resistance without increasing toxicity.
4Reliability
If conventional antifungal drugs are used to treat Candida infections, then treatment is provided, but drug resistance develops
Solution Approach 1:
The composite formulation combines two antifungal agents with different modes of action: Amphotericin B (polyene) that binds to ergosterol in fungal cell membranes, and ionic liquids that disrupt membrane integrity through electrostatic interactions and hydrophobic effects. This multi-target approach reduces the likelihood of resistance development as the fungus would need to simultaneously overcome multiple distinct mechanisms of action.
Solution Approach 2:
The formulation employs sequential or combination therapy where ionic liquids and Amphotericin B work in coordinated fashion. The ionic liquids can initially disrupt the fungal membrane, increasing permeability and enhancing subsequent Amphotericin B entry and action, creating a temporally coordinated attack that prevents resistance mechanisms from developing effectively.
Data Source
AI summary
Provided herein are ionic liquids that can be used as antifungal agents alone or in combination with Amphotericin B. Also disclosed are methods of synthesis of the ionic liquids and inhibiting fungal growth and methods of treating fungal infections using the disclosed compounds. The disclosure provides antifungal agents that potentiate the antifungal activity of Amphotericin B, a commonly used antifungal drug that could be used alone or in combination. This combination will help control and combat the infections caused by drug resistant Candida. auris in immunocompromised patients.